CO6592086A2 - Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion - Google Patents
Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacionInfo
- Publication number
- CO6592086A2 CO6592086A2 CO12146129A CO12146129A CO6592086A2 CO 6592086 A2 CO6592086 A2 CO 6592086A2 CO 12146129 A CO12146129 A CO 12146129A CO 12146129 A CO12146129 A CO 12146129A CO 6592086 A2 CO6592086 A2 CO 6592086A2
- Authority
- CO
- Colombia
- Prior art keywords
- soluble recombinant
- relates
- denaturation
- need
- recombinant interferon
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title abstract 3
- 108010050904 Interferons Proteins 0.000 title abstract 3
- 238000004925 denaturation Methods 0.000 title abstract 2
- 230000036425 denaturation Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000589540 Pseudomonas fluorescens Species 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se relaciona con la expresión de interferón en P. fluorescens y el desarrollo de un nuevo método para extraer proteínas activas a partir del producto de fermentación utilizando detergentes suaves y sin la necesidad de un proceso de replegado.Características de la Invención: La presente invención se relaciona con el campo de la producción de proteína recombinante en anfitriones bacterianos. Adicionalmente se relaciona con la extracción de la proteína recombinante activa, soluble de una fracción insoluble sin el uso de desnaturalización y sin la necesidad de una etapa de replegado. En particular, la presente invención se relaciona con un proceso de producción para obtener altos niveles de la proteína de interferón Tipo 1 recombinante soluble de un anfitrión bacteriano.Campo de Aplicación: Método para producir rápida y económicamente altos niveles de interferón-í3 recombinante soluble en células anfitrionas de mamífero o bacterianas, sin la necesidad de etapas de desnaturalización y replegado.”
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31067110P | 2010-03-04 | 2010-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6592086A2 true CO6592086A2 (es) | 2013-01-02 |
Family
ID=44531690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12146129A CO6592086A2 (es) | 2010-03-04 | 2012-08-28 | Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9187543B2 (es) |
| EP (1) | EP2542574B1 (es) |
| JP (1) | JP5840148B2 (es) |
| KR (1) | KR101857825B1 (es) |
| CN (1) | CN102906108B (es) |
| AU (1) | AU2011223627B2 (es) |
| BR (1) | BR112012022292A2 (es) |
| CA (1) | CA2791361C (es) |
| CL (1) | CL2012002378A1 (es) |
| CO (1) | CO6592086A2 (es) |
| ES (1) | ES2639398T3 (es) |
| MX (1) | MX2012010148A (es) |
| NZ (1) | NZ602255A (es) |
| PE (1) | PE20130557A1 (es) |
| RU (1) | RU2573909C2 (es) |
| WO (1) | WO2011109556A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2542574B1 (en) | 2010-03-04 | 2017-08-09 | Pfenex Inc. | Method for producing soluble recombinant interferon protein without denaturing |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| CN106967175A (zh) * | 2013-05-15 | 2017-07-21 | 复旦大学 | 长效干扰素及其制备方法和用途 |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| CN107099569B (zh) * | 2017-06-30 | 2021-05-07 | 北京生物制品研究所有限责任公司 | 一种规模化发酵生产重组人干扰素β1b蛋白的方法 |
| CN116120424A (zh) * | 2022-06-06 | 2023-05-16 | 江苏靶标生物医药研究所有限公司 | 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| US4462940A (en) | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| US4992271A (en) | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
| US5702699A (en) | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
| US5643566A (en) | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4755465A (en) | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
| US5281532A (en) | 1983-07-27 | 1994-01-25 | Mycogen Corporation | Pseudomas hosts transformed with bacillus endotoxin genes |
| US4695462A (en) | 1985-06-28 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of biological pesticides |
| US4695455A (en) | 1985-01-22 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of pesticides produced by expression of heterologous genes |
| GB8517071D0 (en) | 1985-07-05 | 1985-08-14 | Hoffmann La Roche | Gram-positive expression control sequence |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
| DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
| US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| JP2618618B2 (ja) | 1988-03-04 | 1997-06-11 | 協和醗酵工業株式会社 | 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体 |
| DK174044B1 (da) | 1986-12-23 | 2002-05-06 | Kyowa Hakko Kogyo Kk | Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid....... |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5128130A (en) | 1988-01-22 | 1992-07-07 | Mycogen Corporation | Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens |
| US5055294A (en) | 1988-03-03 | 1991-10-08 | Mycogen Corporation | Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens |
| CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US6372206B1 (en) | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5169760A (en) | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
| GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
| DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| WO1992006116A1 (en) | 1990-09-28 | 1992-04-16 | Ortho Pharmaceutical Corporation | Hybrid growth factors |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5240834A (en) | 1991-01-22 | 1993-08-31 | Albert Einstein College Of Medicine Of Yeshiva University | Solubilization of protein after bacterial expression using sarkosyl |
| DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
| US6171824B1 (en) | 1991-08-30 | 2001-01-09 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
| US6057133A (en) | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
| ITFI940106A1 (it) | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| RU2098124C1 (ru) * | 1994-10-24 | 1997-12-10 | Общество с ограниченной ответственностью "Ниготек" | Способ получения интерферона |
| US5814485A (en) | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
| IT1285405B1 (it) | 1995-06-06 | 1998-06-03 | Alza Corp | Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto. |
| EP1032428B1 (en) | 1997-11-20 | 2003-06-18 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
| EP1088888A4 (en) | 1998-05-14 | 2005-03-16 | Merck Patent Gmbh | MERGED PROTEIN |
| US20030167531A1 (en) | 1998-07-10 | 2003-09-04 | Russell Douglas A. | Expression and purification of bioactive, authentic polypeptides from plants |
| WO2000049146A1 (en) | 1999-02-18 | 2000-08-24 | Rmf Dictagene S.A. | Malaria vaccine |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| KR100358948B1 (ko) | 2000-03-31 | 2002-10-31 | 한국과학기술원 | 인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균 |
| CA2421757A1 (en) | 2000-09-08 | 2002-03-14 | Massachusetts Institute Of Technology | G-csf analog compositions and methods |
| IL155788A0 (en) | 2000-11-07 | 2003-12-23 | Chiron Corp | Stabilized interferon compositions |
| PL363501A1 (en) | 2001-02-06 | 2004-11-29 | Merck Patent Gmbh | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity |
| BR0207267A (pt) | 2001-02-19 | 2004-02-10 | Merck Patent Gmbh | Proteìnas artificiais com imunogenicidade reduzida |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| MXPA04000231A (es) | 2001-07-11 | 2004-05-04 | Maxygen Holdings Ltd | Conjugados del factor de estimulacion de colonias de granulocitos. |
| AU2002330091A1 (en) | 2001-09-10 | 2003-03-24 | Emd Biosciences, Inc. | Method for recovering and analyzing a cellular component of cultured cells without having to harvest the cells first |
| US20040247562A1 (en) | 2001-09-28 | 2004-12-09 | Sang Yup Lee | Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3 |
| CN1635901B (zh) | 2001-10-10 | 2012-03-28 | 诺和诺德公司 | 肽的重构和糖缀合的方法 |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| SI21273A (sl) | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
| WO2004020576A2 (en) | 2002-08-31 | 2004-03-11 | Cj Corp. | Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| US8399217B2 (en) | 2003-03-14 | 2013-03-19 | Brookhaven Science Associates, Llc | High density growth of T7 expression strains with auto-induction option |
| KR101237651B1 (ko) | 2003-11-19 | 2013-02-27 | 다우 글로벌 테크놀로지스 엘엘씨 | 개선된 단백질 발현 시스템 |
| EP2327718B1 (en) | 2003-11-21 | 2016-03-23 | Pfenex, Inc. | Improved expression systems with SEC-system secretion |
| KR100524872B1 (ko) * | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| AU2005206951B2 (en) | 2004-01-16 | 2010-08-19 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
| DK1828242T3 (da) | 2004-12-20 | 2011-04-04 | Cadila Healthcare Ltd | Fremgangsmåde til fremstilling af beta-interferon i høje koncentrationer |
| EP1828241A1 (en) | 2004-12-23 | 2007-09-05 | Laboratoires Serono S.A. | G-csf polypeptides and uses thereof |
| GB0605684D0 (en) | 2006-03-21 | 2006-05-03 | Sicor Biotech Uab | Method For Purifying Granulocyte-Colony Stimulating Factor |
| AU2007254993A1 (en) | 2006-05-30 | 2007-12-13 | Dow Global Technologies Llc | Codon optimization method |
| EP1939212A1 (en) * | 2006-12-20 | 2008-07-02 | LEK Pharmaceuticals D.D. | Organic compounds |
| KR101491867B1 (ko) | 2007-01-31 | 2015-02-10 | 피페넥스 인크. | 증가된 발현을 위한 박테리아 리더 서열 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN101688213A (zh) | 2007-04-27 | 2010-03-31 | 陶氏环球技术公司 | 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法 |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| WO2009023270A2 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| US8940878B2 (en) | 2009-06-25 | 2015-01-27 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| EP2542574B1 (en) | 2010-03-04 | 2017-08-09 | Pfenex Inc. | Method for producing soluble recombinant interferon protein without denaturing |
| PL2552949T3 (pl) | 2010-04-01 | 2017-01-31 | Pfenex Inc. | Sposoby wytwarzania G-CSF w komórce gospodarza Pseudomonas |
-
2011
- 2011-03-02 EP EP11751317.6A patent/EP2542574B1/en not_active Not-in-force
- 2011-03-02 WO PCT/US2011/026921 patent/WO2011109556A2/en active Application Filing
- 2011-03-02 NZ NZ602255A patent/NZ602255A/en not_active IP Right Cessation
- 2011-03-02 CA CA2791361A patent/CA2791361C/en not_active Expired - Fee Related
- 2011-03-02 ES ES11751317.6T patent/ES2639398T3/es active Active
- 2011-03-02 CN CN201180021026.9A patent/CN102906108B/zh not_active Expired - Fee Related
- 2011-03-02 BR BR112012022292A patent/BR112012022292A2/pt not_active IP Right Cessation
- 2011-03-02 PE PE2012001389A patent/PE20130557A1/es not_active Application Discontinuation
- 2011-03-02 KR KR1020127025760A patent/KR101857825B1/ko not_active Expired - Fee Related
- 2011-03-02 US US13/039,183 patent/US9187543B2/en not_active Expired - Fee Related
- 2011-03-02 MX MX2012010148A patent/MX2012010148A/es unknown
- 2011-03-02 RU RU2012141653/10A patent/RU2573909C2/ru not_active IP Right Cessation
- 2011-03-02 AU AU2011223627A patent/AU2011223627B2/en not_active Ceased
- 2011-03-02 JP JP2012556223A patent/JP5840148B2/ja not_active Expired - Fee Related
-
2012
- 2012-08-28 CO CO12146129A patent/CO6592086A2/es unknown
- 2012-08-29 CL CL2012002378A patent/CL2012002378A1/es unknown
-
2015
- 2015-10-15 US US14/884,081 patent/US9611499B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2791361C (en) | 2018-06-12 |
| JP2013524775A (ja) | 2013-06-20 |
| WO2011109556A2 (en) | 2011-09-09 |
| PE20130557A1 (es) | 2013-05-19 |
| EP2542574A2 (en) | 2013-01-09 |
| ES2639398T3 (es) | 2017-10-26 |
| US9187543B2 (en) | 2015-11-17 |
| EP2542574A4 (en) | 2014-01-29 |
| US9611499B2 (en) | 2017-04-04 |
| CN102906108B (zh) | 2016-01-20 |
| US20160032345A1 (en) | 2016-02-04 |
| US20110217784A1 (en) | 2011-09-08 |
| JP5840148B2 (ja) | 2016-01-06 |
| KR20130018743A (ko) | 2013-02-25 |
| CA2791361A1 (en) | 2011-09-09 |
| AU2011223627B2 (en) | 2015-06-18 |
| NZ602255A (en) | 2014-04-30 |
| MX2012010148A (es) | 2013-01-22 |
| RU2012141653A (ru) | 2014-04-10 |
| AU2011223627A1 (en) | 2012-09-27 |
| KR101857825B1 (ko) | 2018-05-14 |
| CN102906108A (zh) | 2013-01-30 |
| CL2012002378A1 (es) | 2014-01-10 |
| BR112012022292A2 (pt) | 2017-01-10 |
| WO2011109556A3 (en) | 2012-01-12 |
| EP2542574B1 (en) | 2017-08-09 |
| RU2573909C2 (ru) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6592086A2 (es) | Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| WO2019224025A3 (en) | Antagonizing cd73 antibody | |
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
| EP3564259A3 (en) | Recognition tags for tgase-mediated conjugation | |
| WO2012045082A3 (en) | Engineered nucleic acids and methods of use thereof | |
| EA201991976A1 (ru) | Метаболически оптимизированная клеточная культура | |
| BR112016023769A2 (pt) | célula hospedeira recombinante para a expressão de proteínas de interesse | |
| EA201190326A8 (ru) | Полипептиды гормона роста и способы их получения и применения | |
| WO2015158808A3 (en) | Recombinant host cell engineered to overexpress helper proteins | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| PH12022550693A1 (en) | Multi-specific binding proteins for cancer treatment | |
| EA201791761A1 (ru) | Композиция на основе олеаноил-пептида и повышение содержания коллагена | |
| AR083354A1 (es) | Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto | |
| WO2013058594A3 (ko) | 항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도 | |
| NZ590143A (en) | Anti-inflammatory proteins and methods of preparation and use thereof | |
| IN2015DN03206A (es) | ||
| AR072832A1 (es) | LINEAS DE CELULAS HOSPEDANTES DE PRODUCCION MEJORADA QUE CONTIENEN CONSTRUCCIONES DE VECTORES QUE COMPRENDEN UN CASETE DE EXPRESIoN DE DHFR (ENZIMA DIHIDROFOLATO REDUCTASA). | |
| AR101597A1 (es) | Proteínas de fusión uti (inhibidor de tripsina urinaria) | |
| MY182519A (en) | Method for producing lipid using acyl-acp thioesterase | |
| WO2013134129A3 (en) | Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins | |
| AR076774A1 (es) | INGENIERIA EPIGENETICA POR MEDIO DE UNA MENOR METILACION DEL ARN RIBOSOMAL OCASIONADA POR UNA DISMINUCION DE LA EXPRESION DE LA PROTEINA 5 DE INTERACCIoN CON EL FACTOR DE TERMINACIoN DE TRANSCRIPCION 1 (TIP-5) | |
| CL2019003459A1 (es) | Métodos de cultivo celular. | |
| ZA202007135B (en) | Plant produced porcine circovirus pseudovirion |